Pargyline is a monoamine oxidase inhibitor with antihypertensive properties.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Alfuzosin | Alfuzosin may increase the hypotensive activities of Pargyline. |
| Amifostine | Pargyline may increase the hypotensive activities of Amifostine. |
| Diazoxide | Diazoxide may increase the hypotensive activities of Pargyline. |
| Obinutuzumab | Pargyline may increase the hypotensive activities of Obinutuzumab. |
| Pentoxifylline | Pentoxifylline may increase the hypotensive activities of Pargyline. |
| Rituximab | Pargyline may increase the hypotensive activities of Rituximab. |
| Epicaptopril | Epicaptopril may decrease the antihypertensive activities of Pargyline. |
| Siponimod | Siponimod may decrease the antihypertensive activities of Pargyline. |
| Selpercatinib | Selpercatinib may decrease the antihypertensive activities of Pargyline. |
| Naxitamab | Naxitamab may decrease the antihypertensive activities of Pargyline. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Pargyline. |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Pargyline. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Pargyline. |
| Hydroxyzine | Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Pargyline. |
| Magnesium sulfate | The therapeutic efficacy of Pargyline can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | Pargyline may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Metyrosine | Pargyline may increase the sedative activities of Metyrosine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Pargyline. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Pargyline. |
| Orphenadrine | Pargyline may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | Pargyline may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of Pargyline. |
| Pramipexole | Pargyline may increase the sedative activities of Pramipexole. |
| Ropinirole | Pargyline may increase the sedative activities of Ropinirole. |
| Rotigotine | Pargyline may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Pargyline. |
| Sodium oxybate | Pargyline may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. |
| Suvorexant | Pargyline may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Thalidomide | Pargyline may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | Pargyline may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Desmopressin | Desmopressin may decrease the antihypertensive activities of Pargyline. |
| Cyclosporine | Cyclosporine may decrease the antihypertensive activities of Pargyline. |
| Methylergometrine | Methylergometrine may decrease the antihypertensive activities of Pargyline. |
| Nicergoline | Nicergoline may decrease the antihypertensive activities of Pargyline. |
| Phenmetrazine | Phenmetrazine may decrease the antihypertensive activities of Pargyline. |
| Dutasteride | Dutasteride may decrease the antihypertensive activities of Pargyline. |
| Propafenone | Propafenone may decrease the antihypertensive activities of Pargyline. |
| Finasteride | Finasteride may decrease the antihypertensive activities of Pargyline. |
| Ephedrine | Ephedrine may decrease the antihypertensive activities of Pargyline. |
| 1-benzylimidazole | 1-benzylimidazole may decrease the antihypertensive activities of Pargyline. |
| Dronedarone | Dronedarone may decrease the antihypertensive activities of Pargyline. |
| Amibegron | Amibegron may decrease the antihypertensive activities of Pargyline. |
| Nylidrin | Nylidrin may decrease the antihypertensive activities of Pargyline. |
| Solabegron | Solabegron may decrease the antihypertensive activities of Pargyline. |
| Saralasin | Saralasin may decrease the antihypertensive activities of Pargyline. |
| Tyramine | Tyramine may decrease the antihypertensive activities of Pargyline. |
| Mirabegron | Mirabegron may decrease the antihypertensive activities of Pargyline. |
| Adrafinil | Adrafinil may decrease the antihypertensive activities of Pargyline. |
| Etilefrine | Etilefrine may decrease the antihypertensive activities of Pargyline. |
| Synephrine | Synephrine may decrease the antihypertensive activities of Pargyline. |
| Moxisylyte | Moxisylyte may decrease the antihypertensive activities of Pargyline. |
| Dihydroergocornine | Dihydroergocornine may decrease the antihypertensive activities of Pargyline. |
| DL-Methylephedrine | DL-Methylephedrine may decrease the antihypertensive activities of Pargyline. |
| Amitraz | Amitraz may decrease the antihypertensive activities of Pargyline. |
| Atipamezole | Atipamezole may decrease the antihypertensive activities of Pargyline. |
| Ractopamine | Ractopamine may decrease the antihypertensive activities of Pargyline. |
| Anisodamine | Anisodamine may decrease the antihypertensive activities of Pargyline. |
| Tulobuterol | Tulobuterol may decrease the antihypertensive activities of Pargyline. |
| Dopexamine | Dopexamine may decrease the antihypertensive activities of Pargyline. |
| Idazoxan | Idazoxan may decrease the antihypertensive activities of Pargyline. |
| Higenamine | Higenamine may decrease the antihypertensive activities of Pargyline. |
| Reproterol | Reproterol may decrease the antihypertensive activities of Pargyline. |
| Theodrenaline | Theodrenaline may decrease the antihypertensive activities of Pargyline. |
| Tramazoline | Tramazoline may decrease the antihypertensive activities of Pargyline. |
| Octopamine | Octopamine may decrease the antihypertensive activities of Pargyline. |
| Fenozolone | Fenozolone may decrease the antihypertensive activities of Pargyline. |
| Dihydroergocristine | Dihydroergocristine may decrease the antihypertensive activities of Pargyline. |
| Norfenefrine | Norfenefrine may decrease the antihypertensive activities of Pargyline. |
| Dihydroergocryptine | Dihydroergocryptine may decrease the antihypertensive activities of Pargyline. |
| Oxyfedrine | Oxyfedrine may decrease the antihypertensive activities of Pargyline. |
| Terguride | Terguride may decrease the antihypertensive activities of Pargyline. |
| Xenon | The risk or severity of adverse effects can be increased when Xenon is combined with Pargyline. |
| Rimiterol | Rimiterol may decrease the antihypertensive activities of Pargyline. |
| Tretoquinol | Tretoquinol may decrease the antihypertensive activities of Pargyline. |
| Prenalterol | Prenalterol may decrease the antihypertensive activities of Pargyline. |
| Xamoterol | Xamoterol may decrease the antihypertensive activities of Pargyline. |
| Mefenorex | Mefenorex may decrease the antihypertensive activities of Pargyline. |
| Deoxyepinephrine | Deoxyepinephrine may decrease the antihypertensive activities of Pargyline. |
| Quinoline Yellow WS | Quinoline Yellow WS may decrease the antihypertensive activities of Pargyline. |
| Apraclonidine | Pargyline may increase the alpha-adrenergic activities of Apraclonidine. |
| Atomoxetine | The risk or severity of adverse effects can be increased when Pargyline is combined with Atomoxetine. |
| Betahistine | The metabolism of Betahistine can be decreased when combined with Pargyline. |
| Bezafibrate | Pargyline may increase the hepatotoxic activities of Bezafibrate. |
| Buprenorphine | Pargyline may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Bupropion | The risk or severity of adverse effects can be increased when Pargyline is combined with Bupropion. |
| Buspirone | The risk or severity of hypertension can be increased when Pargyline is combined with Buspirone. |
| Carbamazepine | The risk or severity of adverse effects can be increased when Carbamazepine is combined with Pargyline. |
| Cyclobenzaprine | Cyclobenzaprine may increase the serotonergic activities of Pargyline. |
| Cyproheptadine | Pargyline may increase the anticholinergic activities of Cyproheptadine. |
| Dextromethorphan | The risk or severity of serotonin syndrome can be increased when Pargyline is combined with Dextromethorphan. |
| Diethylpropion | The risk or severity of adverse effects can be increased when Pargyline is combined with Diethylpropion. |
| Domperidone | The risk or severity of QTc prolongation, torsade de pointes, and cardiotoxicity can be increased when Pargyline is combined with Domperidone. |
| Hydrocodone | Pargyline may increase the serotonergic and central nervous system depressant (CNS depressant) activities of Hydrocodone. |
| Hydromorphone | Pargyline may increase the serotonergic activities of Hydromorphone. |
| Isometheptene | Pargyline may increase the sympathomimetic activities of Isometheptene. |
| Levonordefrin | Pargyline may increase the hypertensive activities of Levonordefrin. |
| Lithium citrate | The risk or severity of serotonin syndrome can be increased when Pargyline is combined with Lithium citrate. |
| Lithium carbonate | The risk or severity of serotonin syndrome can be increased when Pargyline is combined with Lithium carbonate. |
| Lithium hydroxide | The risk or severity of serotonin syndrome can be increased when Pargyline is combined with Lithium hydroxide. |
| Maprotiline | The risk or severity of adverse effects can be increased when Pargyline is combined with Maprotiline. |